FDA announces public workshop to discuss third-party refurb docket

FDA announces public workshop to discuss third-party refurb docket

by Christina Hwang, Contributing Reporter | July 21, 2016
Business Affairs HTM Medical Devices Parts And Service Risk Management
Workshop to be held in Maryland
on October 27 and 28
Now that the commenting period has ended, the FDA plans to host a two-day public workshop for stakeholders to discuss the questions raised in its third-party service and refurbished medical device docket.

In March, the FDA introduced a docket that sets out to specifically define terms pertaining to the non-OEM medical industry. Interest in it, sparked by safety concerns, has sent shock waves through a third-party industry eager to defend its reputation and fearful of regulations that might hurt its business.

For OEMs the docket is generally regarded as an opportunity to gain greater clarity about what they can and cannot be held accountable for in situations where a third-party has taken over control of their machinery.

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

The workshop, to be held on October 27 and 28 at the FDA's campus in Silver Spring, Maryland, will aim to move the needle on issues central to the docket:

  • Establish working definitions for third-party and (original equipment manufacturer) OEM activities.

  • Discuss benefits and challenges that stakeholders encounter, potential benefits and risks to patients/users, and failure modes of devices introduced as a result of performing activities associated with third-party entities.

  • Identify current best practices and discuss alternative methods to mitigate risks associated with performing activities associated with third-party entities.

  • Determine whether specific procedures are necessary for each activity as it relates to third-party services performed.

“FDA is currently reviewing all of the comments and will use them to inform a set of working questions designed to promote an understanding of challenges and best practices to mitigate risks associated with these activities,” said the FDA in the Federal Register.

The docket received 176 comments from a wide range of stakeholders. Look for the August issue of HealthCare Business News magazine for an in-depth report on those responses.

You Must Be Logged In To Post A Comment